Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2
The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.
The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.
The Anti-Coagulation Video Channel* is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with atrial fibrillation (AF) or venous thromboembolism (VTE). It provides an overview of how to prevent stroke and systemic embolism in nonvalvular AF patients and how to prevent and treat VTE.
Users can expect to find the following videos readily available on the video channel with regular updates:
The benefits of dabigatran in preventing stroke in atrial fibrillation patients (Hans-Christoph Diener, Gregory YH Lip and John Eikelboom)
Dabigatran for the treatment and prevention of DVT and PE (Samuel Z Goldhaber)
The safety profile of dabigatran (Hans-Christoph Diener, John Eikelboom and Jeffrey Weitz)
Healthcare professionals should return often to avoid missing out on new content.
*The Anti-Coagulation Video Channel has been supported by an educational grant from Boehringer Ingelheim, who provided the videos, and is intended for healthcare professionals outside the USA, Canada and UK.
COPD affects an estimated 210 million people worldwide and is now the 3rd leading cause of death (WHO 2015). Patients with Chronic Obstructive Pulmonary Disease (COPD) will rank as the fifth leading cause of disability in 2030, accounting for almost 4% of total disability-adjusted life years (DALYs) lost worldwide.1 Many patients with COPD report that the symptoms of COPD are at their worst in the morning and have a major impact on their quality of life.2
The COPD Knowledge Centre has been designed to provide healthcare professionals with free access to educational materials and disease awareness information. This includes epidemiology, pathophysiology and COPD symptoms. Users will also discover the latest guidelines for the diagnosis, treatment and management of the disease.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and prevention of COPD. 2015
Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-2048; Curr Med Res Opin 2012;28:1405 [Erratum].
The Hypogonadism Knowledge Centre is a free resource for healthcare professionals involved in the diagnosis, treatment and monitoring of patients with the condition. Users can expect to find disease awareness sections covering epidemiology, pathophysiology, signs and symptoms and current best practice treatment guidelines.
The publications digest section of this resource is regularly updated with analysis and commentary on recent scientific articles related to male hypogonadism. There are currently over 50 articles available in the publications digest area, which can be filtered by year or by the following comorbidities:
Mood and behaviour
A resources area also contains downloadable materials and links to useful tools, societies and other external websites.
This resource has been produced in collaboration with Bayer AG, with content provided by Bayer AG.
Wouldn't it be great if we could recommend evidence-based, nutritional approaches to help prevent Alzheimer's dementia? Or to slow the progression of cognitive decline in those already living with an Alzheimer's diagnosis? Two recent papers suggest we can do just that.
7 days ago -
A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA).
Background: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis, with significant impact on quality of life and functional status. Whilst biologic disease modifying anti-rheumatic drugs ...
Mon 01 Feb 2016 -
Diabetes, Dementia and Hypoglycemia.
We are experiencing an epidemic of both diabetes and dementia among older adults in this country. The risk for dementia appears to be increased in patients with diabetes, and patients with dementia ...
This guideline covers the clinical care of adults (18 years and over) who are dying during the..
... last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
This guideline includes recommendations on:
- recognising when people are entering the last few days of life
- communicating and shared decision-making
- clinically assisted hydration
- medicines for managing pain, breathlessness, nausea and vomiting, anxiety, delirium, agitation, and noisy respiratory secretions
- anticipatory prescribing
Who is it for?
- Health and social care professionals caring for people who are dying, including those working in primary care, care homes, hospices, hospitals and community care settings such as people’s own homes
- Commissioners and providers of care for people in the last days of life
- People who are dying, their families, carers and other people important to them
Hyperthermia is a frequent complication in up to 50% of patients with acute ischemic stroke, and it..
... was shown to be associated with a poor outcome. On the other end, therapeutically induced hypothermia has shown promising potential in patients with hypoxic encephalopathy and in animal models of focal cerebral ischemia. This document presents the ESO guidelines on temperature management in patients with acute ischemic stroke. The aim of this Guideline document is to assist physicians treating patients with acute ischemic stroke in their clinical decisions with regard to the management of temperature.
Dementia is becoming increasingly prevalent, both due to our ageing population and improved recognition of the condition. However, the nature of dementia means that managing the condition can pose unique...
This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and ...